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Received September 28, 1998; returned to author for revision November 5, 1998; accepted November 19, 1998
Antibodies (Abs) can contribute to the cure of a viral infection, in principle, in two ways by: (1) binding to infected cells and
thereby reducing the production of progeny virus [here termed cell-targeting (CT) activity] and (2) reacting with released
progeny virus and thereby inhibiting the spread of the infection [termed virus neutralizing (VN) activity]. We have previously
shown that a pulmonary influenza virus infection in severe combined immunodeficient mice could be cured by treatment of
these mice with hemagglutinin (HA)-specific monoclonal Abs (mAbs) that mediated both of the above activities. Although the
therapeutic activity of these mAbs correlated with their VN activity, it remained unclear how much their CT activity
contributed to the Ab-mediated recovery process. To clarify this point, we tested the therapeutic efficacy of two mAbs of
IgG2a isotype that mediated CT but no VN activity: one specific for the viral neuraminidase and the other for matrix protein
2. Both mAbs reduced pulmonary virus titers by 100- to 1000-fold but they failed to clear the infection, even when
administered in combination and at therapeutically saturating concentrations. The results suggest that CT activity contributes
significantly also to the therapeutic activity of HA-specific mAbs and further support the notion that VN-activity is required
for Ab-mediated virus clearance. © 1999 Academic Press
f
t
v
t
i
D
a
p
p
T
c
o
i
m
d
o
i
c
o
a
(
s
b
m
m
a
iINTRODUCTION
Influenza type A virus remains a major threat for hu-
an health and is responsible, on average, for ;20,000
nfection-related deaths per year in the United States
lone (Simonson et al., 1996). Mechanisms that contrib-
te to protection against and recovery from this infection
ave been studied extensively in mice, which provide a
ood model for different forms of the disease including
nfection of the upper respiratory tract (RT)2 and the
linically much more severe infection of the lower RT
Yetter et al., 1980; Novak et al., 1993). Current evidence
ndicates that components of both innate and adaptive
mmune systems contribute to the control of the infec-
ion, that T cell function is required for its ultimate reso-
ution, that either CD41 or CD81 T cells can provide this
1 To whom reprint requests should be addressed. Fax: (215) 898-
868. E-mail: gerhard@wistar.upenn.edu.
2 Abbreviations used: Ab, antibody; BSA, bovine serum albumin; CR,
omplement receptor; CT, cell targeting; ELISA, enzyme-linked immu-
osorbent assay; FCM, flow cytometry; FCS, fetal calf serum; HA,
emagglutinin; HAU, hemagglutinating units; Het-I, heterosubtypic im-
unity; i.n., intranasal; ip, intraperitoneal; ISC-CM, Iscove’s complete
edium; M2, matrix protein 2; mAbs, monoclonal antibodies; MDCK,
adin–Darby canine kidney; MID50, mouse infectious doses; NA, neur-
minidase; p.i., postinfection; PBS, phosphate-buffered saline; PBSN,
BS containing 0.04% NaN3; RT, respiratory tract; SCID, severe com-
ined immunodeficient; TCID50, tissue culture infectious doses; VN,cirus neutralizing.
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138unction, and that different mechanisms play key roles in
he recovery process promoted by these T cell subsets:
irus clearance by CD81 T cells appears to be based on
he cognate interaction with and subsequent killing of
nfected epithelial cells (Lukacher et al., 1984; Hou and
oherty, 1995; Doherty et al., 1997) while the promotion of
T-cell-dependent antiviral antibody (Ab) response ap-
ears to underlie the CD41 T-cell-mediated recovery
rocess (Scherle et al., 1992; Mozdzanowska et al., 1997;
opham and Doherty, 1998).
To identify the mechanism by which the Ab response
ontributes to virus clearance, we examined the effects
f passive monoclonal Ab (mAb) on the course of the
nfection in severe combined immunodeficient (SCID)
ice. In principle, Ab may combat the infection at two
istinct stages of the virus replication cycle: (1) the stage
f production of progeny virus through reaction with
nfected host cells, activities collectively referred to as
ell targeting (CT) activity, and (2) the stage of the spread
f the infection by reaction with released progeny virus,
ctivities collectively referred to as virus neutralization
VN) if they inhibit virus spread. We have previously
hown that an established infection in SCID mice could
e cured by treatment with hemagglutinin (HA)-specific
Abs and that the therapeutic activity of HA-specific
Abs correlated with their VN activity (Mozdzanowska et
l., 1997). However, since these HA-specific mAbs exhib-
ted also CT activity, the degree to which the latter activity
ontributed to the recovery process remained unclear.
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139THERAPEUTIC ACTIVITY OF ANTIBODY IN INFLUENZA INFECTIONur main evidence against a significant role of CT activ-
ty was the finding that treatment of infected SCID mice
ith a mAb specific for the viral transmembrane matrix
rotein 2 (M2), which reacted with viable infected cells
ut exhibited no VN activity in vitro, had no significant
ffect on the course of the infection (Palladino et al.,
995). The caveat was that the M2-specific mAb was of
he IgG1 isotype, which had been found in other exper-
mental systems to be less effective in vivo than the
gG2a isotype displayed by the above-mentioned HA-
pecific mAbs (Denkers et al., 1985; Kaminski et al., 1986;
aldrige and Buchmeier, 1992; Schlesinger et al., 1993).
To address this problem, we selected an IgG2a switch
ariant from the parental M2-specific hybridoma and
ssessed its therapeutic activity in infected SCID mice.
n addition, we measured the therapeutic activity of a
Ab specific for the third viral transmembrane protein,
euraminidase (NA), which, similar to the anti-M2 mAb,
acked VN activity in vitro and was of IgG2a isotype. Both
Abs reduced pulmonary virus titers in SCID mice. How-
ver, in contrast to HA-specific mAbs, they failed to clear
he infection. The results show that, depending on IgG
sotype, Ab-mediated CT activity can make a significant
ontribution to the control of influenza virus infection in
ivo and support the previous conclusion that VN activity
s necessary for Ab-mediated virus clearance.
RESULTS
unctional activities of the M2- and NA-specific mAbs
n vitro
Reaction of the mAbs with M2 and NA expressed in
he plasma membrane of infected cells was tested by
nzyme-linked immunosorbent assay (ELISA) and flow
ytometry (FCM). For comparison, the HA-specific mAb
35-C12, which has been analyzed previously for its
herapeutic activity in vivo (Mozdzanowska et al., 1997),
as included in these analyses. In addition, a M1-spe-
ific mAb, which is directed to a viral protein expressed
nly intracellularly, was included to verify that these as-
ays detected only viral antigen expressed in the plasma
embrane and accessible to antibody on intact infected
ells. When tested by ELISA for binding to infected for-
alin-fixed Madin–Darby canine kidney (MDCK) cells,
he M2-, NA-, and HA-specific mAbs showed comparable
eaction at low concentration but differed in their satu-
ation binding. To exclude the possibility that formalin
ixation differentially affected the reactions seen in the
LISA, the mAbs were additionally tested by FCM for
eaction with viable infected P1.HTR and EL4 cells (Fig.
B). These assays confirmed that HA was expressed at
ighest density and indicated that, at least in these cell
ines, M2 was expressed at higher density than NA. The
A values of these mAbs were measured in their reaction
ith infected EL4 cells and found to be (2.1 6 0.3) 3 108
21 for the HA-, (2.3 6 0.2) 3 108 M21 for the M2-, and t24 6 14) 3 108 M21 for the NA-specific mAb. [The KA of
.8 3 107 M21 was previously obtained by plasmon
esonance for the reaction of the same HA-specific mAb
ith purified HA (Mozdzanowska et al., 1997); the reason
or the discrepancy between these measurements has
ot been determined].
The M2- and NA-specific mAbs exhibited no detect-
ble HA inhibition (HAI) or VN activity at 10 mg/ml, even
n the presence of serum components (Table 1). H35-C12
as similar except that its VN activity was greatly en-
anced by serum (note that low activity in these assays
s atypical for HA-specific antibodies and is a peculiarity
f antibodies directed to site Cb on HA).
A typical antiviral function of M2- and NA-specific
ntibodies is their ability to reduce virus plaque size
hen they are incorporated into the agar overlay (Seto
nd Rott, 1966; Webster et al., 1968; Zebedee and Lamb,
988). To make this assay more quantitative, we mea-
ured the ability of these mAbs to suppress virus yield in
iquid cultures. In agreement with the study of Zebedee
nd Lamb (1988), the M2-specific mAb did not reduce the
ield of PR8 (Fig. 2A) but was effective against several
ther influenza virus strains (data not shown). The failure
FIG. 1. Reaction of mAbs with viral determinants expressed on
lasma membrane of infected cells. (A) mAbs were tested by ELISA for
eaction with PR8-infected fixed MDCK cell monolayers. The cells were
sed 8 h p.i. (B) mAbs were tested by FCM for reaction with viable
R8-infected P1.HTR and EL-4 cells. The cells were tested 14–17 h p.i.
ach symbol shows the average mean fluorescence intensity of three
ndependent assays. mAbs were used at 0.25 to 1 mg/106 cells. Viable
ells were gated by forward and right-angle scatter and 5000 events
ere analyzed.o inhibit PR8 may be related to the insensitivity of this
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140 MOZDZANOWSKA ET AL.irus strain to amantadine, a virus growth-suppressing
rug that also targets the M2 protein (Zebedee and
amb, 1988). The NA-specific mAb suppressed virus
ield when present at 20 mg and 7 mg/ml (Fig. 2B), but
as 30–100 times less effective in this assay than the
A-specific mAb H35-C12 (Fig. 2C; note the lower con-
entration used in the case of H35-C12). Interestingly,
oth NA- and HA-specific mAbs had only a temporary
uppressive effect on virus yield, delaying it by ;2 days
ompared to control cultures. The delayed virus yield in
hese cultures was not due to the outgrowth of antigenic
scape mutants (data not shown).
T
Ab Activates
Assay
mg
14C2 s-M2
(G2a)
NA-112 a
NA (G2a
AI vs intact virus . 10 . 10
N without serum . 10a . 10a
N with serum (1.6%) . 10 . 10
rophylaxis in vivo . 200 (0/6) . 200 (0/7
Note. Ab activities against PR8 virus were determined as described
f two to five independent determinations. Prophylatic activity indicate
revented infection in 50% of SCID mice. Data in parentheses show the
35-C12 are from Mozdzanowska et al. (1997)).
a The small in vitro VN activity previously attributed to these mAbs (Ge
sed mAb preparations by HA-specific mAb.
FIG. 2. Reduction of virus yield by mAb in vitro. MDCK cell cultures w
resence of antibody at various concentrations. The progress of the vir
he medium at the indicated time points. Virus yield from control cultur
he antibody concentrations are in (A) anti-M2 at 20 mg/ml (squares); in
n (C) anti-HA a 2 mg/ml (squares), 0.7 mg/ml (diamonds), 0.2 mg/ml (tria
iter from three cultures.he M2- and NA-specific mAbs lack VN activity
n vivo
While some mechanisms that contribute to VN are
ikely to operate similarly in vitro and in vivo (such as
revention of adsorption of virus to host cells by HA-
pecific Abs), others may operate only in vivo. For in-
tance, Ab bound to NA and M2 may promote uptake and
egradation of the opsonized virus by FcR- and comple-
ent receptor (CR)-expressing cells as shown, for in-
tance, with yellow fever virus (Schlesinger and Chap-
an, 1995). Also, NA-specific Abs may result in VN indi-
and in Vivo
hich Ab exhibits one unit of activity
H35-C12
a-HA (Cb)
(G2a)
H16-L10
a-NP (G2a)
M2-1C6
a-M1 (G1)
. 10 . 10 . 10
2.5 . 10 . 10
0.03 . 10 . 10
20 (4/4) . 200 (0/5) . 200 (0/5)
Materials and Methods. Data from the in vitro assays are the means
ose of mAb (given intraperitoneally 6 h prior to virus challenge) that
er of protected/total tested at a dosage of 200 mg/mouse. The data of
t al., 1997) appeared to result from a minor contamination of previously
fected at low multiplicity and subsequently cultured in the continuous
ction was monitored by determining the amount of virus released into
hown in each panel as full dots. Each dot is the mean of 12 cultures.
i-NA at 20 mg/ml (squares), 7 mg/ml (diamonds), and 2 mg/ml (triangle);
up), and 0.07 mg/ml (triangles, down). Each symbol indicates the meanABLE 1
in Vitro
/ml at w
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141THERAPEUTIC ACTIVITY OF ANTIBODY IN INFLUENZA INFECTIONectly by preventing viral NA from inactivating inhibitors
resent in RT secretions (Klenk and Rott, 1988). Thus, the
ailure of an Ab to neutralize virus in vitro does not
ecessarily mean that the same is true in vivo.
VN activity in vivo was assessed by measuring the
bility of mAbs to prevent infection when given prior to
irus challenge. As prophylaxis requires less Ab than
herapy, it is clear that Ab provides prophylaxis by neu-
ralizing the initial virus inoculum (Mozdzanowska et al.,
997). At 200 mg/mouse, the largest dose tested, M2- and
A-specific mAb showed no prophylactic activity. By
omparison, the HA-specific mAb H35-C12 protected
00% of mice when given prophylactically at 200 mg/
ouse and 50% at a dosage of ;20 mg/mouse (Mozdza-
owska et al., 1997). As expected, mice treated prophy-
actically with 200 mg of mAb to the viral core proteins NP
nd M1 were not protected.
Taken together, the data show that the M2- and NA-
pecific mAbs, like the HA-specific mAb, reacted well
ith determinants of native viral proteins expressed in
he plasma membrane of infected cells and thus had the
otential of mediating CT activity, but, unlike the HA-
pecific mAb, they lacked significant VN activity in vivo.
hen given after infection, M2- and NA-specific
Abs reduce virus growth in the lung but fail
o clear the infection
The therapeutic activity of mAbs was tested by treating
CID mice 6–24 h after infection with mAb and measur-
ng virus titer in the lung 6–15 days later. Figure 3 shows
he data from two experiments in which SCID mice were
reated with mAb 1 day after infection and lung virus
iters were determined on day 14. The M2-specific mAb
as administered in both experiments as single dose of
00 mg/mouse. The NA-specific mAb was given in the
irst experiment as single dose of 200 mg/mouse and in
he second experiment in multiple doses [200 mg on day
, 100 mg on day 3, and 50 mg on day 5, all intraperito-
eally (ip)]. The latter was done to compensate for the
horter half-life of the NA-specific mAb, which was ;2
ays compared to the half-life of 7–8 days for typical
Abs of G2a isotype. The reason for the reduced half-life
f the NA-specific mAb is currently not known.
The experiments (Fig. 3A) showed that treatment of
nfected SCID mice with these mAbs resulted in a sig-
ificant reduction of pulmonary virus titers but failed to
lear the infection. This failure was not due to the out-
rowth of antigenic escape mutants (data not shown).
urthermore, the failure to clear the infection was not
ue to usage of a supoptimal Ab dose as the therapeutic
fficacy of both mAbs seemed to be maximal at 200
g/mouse (Fig. 3B). Thus, while both mAbs inhibited
irus growth in the lung, they were not effective enough
o clear the infection. By comparison, treatment of in-
ected SCID mice with 200 mg of H35-C12 cleared the mnfection in 100% of the mice (Mozdzanowska et al.,
997).
herapeutic activity of mixtures of mAbs
As Ab-mediated CT activity has been shown in other
ystems to be influenced by the density of the target
ntigen (Kummer et al., 1990; Yousaf et al., 1993), we
ondered whether the therapeutic activity would be en-
anced if both mAbs were administered simultaneously.
s shown in Figs. 4A and 4B, combining M2- and NA-
pecific mAbs did not improve the therapeutic activity.
his observation additionally suggested that both mAbs
ade use of largely overlapping effector mechanisms
nd that each mAb already used these mechanisms to
heir fullest capacity. This conclusion is supported by the
inding that addition of a small dose of the HA-specific
FIG. 3. Therapeutic activity of M2- or NA-specific mAbs in vivo. SCID
ice were infected with PR8 and injected ip 6–24 h later, with M2- or
A-specific mAb. Control mice received PBS instead of mAb. The virus
iter in the lung was determined 6 or 15 days after infection. (A) Data
rom two independent experiments (circles, triangles) are shown. The
2-specific mAb was administered in both experiments at 200 mg/
ouse. The NA-specific mAb was given in the first experiment (circles)
s a single dose of 200 mg on day 1 or, in the second experiment
diamonds), in three doses, 200 mg on day 1, 100 mg on day 3, and 50
g on day 5 (to counteract the reduced half-life of the NA-specific mAb).
irus titer in the lung was determined 15 days after infection. Each point
ndicates the titer from an individual mouse. Asterisks indicate average
iters. Both mAbs resulted in significant (t test: P , 0.05) reduction of
irus titer in the lung compared to controls. The stipulated vertical line
hows the threshold of virus detection. (B) The reduction in virus titer
relative to controls) in mice treated with various doses of mAb is
hown. Each symbol shows the average reduction observed in a group
f four or five experimental mice treated with M2- (triangles) or NA-
pecific (open circles) mAb.Ab, which had no significant therapeutic effect on its
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142 MOZDZANOWSKA ET AL.wn, increased significantly the therapeutic activity of
he M2-/NA-Ab mixture, in this case apparently by con-
ributing a new activity to the Ab-mixture, i.e., VN (Fig.
C).
DISCUSSION
Two mAbs, one directed to the viral transmembrane
rotein M2 and the other to NA, were tested for their
herapeutic activity in influenza virus infection by transfer
nto infected SCID mice. As these mAbs exhibited no
easurable VN activity in vivo but reacted well with
iable infected cells, they provide useful reagents for
nvestigating the therapeutic activity of Ab-mediated CT
ctivity in this infection in vivo. The results show that both
Abs were capable of significantly reducing pulmonary
irus titers in infected SCID mice but failed to resolve the
nfection, even when administered in combination and at
herapeutically saturating concentrations.
The finding that these mAbs suppressed pulmonary
irus titers in infected immunodeficient mice is in line
ith previous studies showing that actively or passively
cquired NA-specific immunity reduced virus titers and
FIG. 4. Therapeutic efficacy of mAb mixtures. SCID mice were
reated (single dose, ip) with the indicated mAb preparations 6–24 h
fter infection with PR8. Lung virus titers were determined 6 days after
nfection. Each circle indicates the titer from an individual mouse.
sterisks indicate the mean titer of each group. The vertical stipulated
ine shows the threshold of virus detection. (A) A single experiment in
hich mice were treated with mAb 6 h after infection. (B and C) The
ombined data from two independent experiments in which mice were
reated with mAb 24 h after infection.ortality in immunocompetent experimental animals sSchulman et al., 1968; Webster et al., 1988; Epstein et al.,
993) and also reduced morbidity and virus shedding in
umans (Murphy et al., 1972; Couch et al., 1974). Previous
tudies of M2-specific immunity have provided more
ariable results. Thus, treatment of immunocompetent
ice with the same M2-specific Mab as used here,
hough of G1 isotype, reduced the pulmonary titer of
/Udorn/72(H3N2) (Treanor et al., 1990), but active im-
unization with vaccinia–M2 recombinants had no de-
ectable protective effects, neither in mice (Epstein et al.,
993) nor in ferrets (Jakeman et al., 1989). By contrast,
mmunization of mice with purified M2 protein decreased
orbidity and mortality but this protection could not be
ransferred with serum from M2-immune mice, suggest-
ng that the observed protection may not be Ab-mediated
Lepushkin et al., 1995). As 20–40 mg of anti-M2 of G2a
sotype/ml serum was needed for substantial therapeutic
ctivity in this study and as the Ab isotype played a role,
t is likely that the discrepancies among previous studies
eflect differences in Ab titers induced by active immu-
ization, in CH isotype, and perhaps also in fine speci-
icity (Hughey et al., 1995) of the M2-specific Ab re-
ponses studied. It is important to also note that previous
tudies, by using immunocompetent hosts capable of
aking an active immune response upon virus chal-
enge, could not resolve, as this study did, whether NA-
r M2-specific Abs were actually effective enough to
lear the infection. The possibility that the two mAbs
sed here are merely devoid of the ability to clear the
nfection for idiosyncratic reasons is unlikely, but cannot
e dismissed entirely.
The reduction in pulmonary virus titer seen in this
tudy can be attributed entirely and unequivocally to
b-mediated CT activity as both mAbs had no measur-
ble VN activity in vivo after systemic administration at
he dosage used here. How did these mAbs operate in
ivo? One possibility is that they suppressed virus yield
irectly, as seen in vitro, upon binding to infected cells
Fig. 2). Such a mechanism appears to account for the
b-mediated suppression of Sindbis (Griffin et al., 1997)
nd measles virus (Schneider-Schaulies et al., 1992) in-
ection in the central nervous system, but it does not
ppear to play a role here. First, the M2-specific mAb did
ot display this activity against PR8 in vitro and there is
o reason to expect the situation to be different in vivo.
econd, in the case of the NA-specific mAb, this activity
n vitro delayed virus yield by 1–2 days only, which makes
t difficult to envision how it could account for reduced
irus titers 6–14 days after infection. Therefore, both
Abs appeared to operate by targeting effectors of the
nnate immune system to infected host cells. This may
nclude complement-mediated activities and CR- and
cR-expressing effector cells. The finding that the an-
i-M2 mAb of G2a isotype was more effective than G1,
nalogous to observations made in other experimental
ystems as well (Denkers et al., 1985; Kaminski et al.,
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143THERAPEUTIC ACTIVITY OF ANTIBODY IN INFLUENZA INFECTION986; Baldrige and Buchmeier, 1992; Schlesinger et al.,
993) is consistent with this conclusion as complement
ctivation by the classic pathway (Neuberger and Rajew-
ky, 1981) and the targeting/activation of FcR-expressing
ffector cells exhibit similar isotypic preferences
Ravetch and Kinet, 1991; Hazenbos et al., 1998; Yuan et
l., 1998).
The ability of the M2-specific mAb to suppress pulmo-
ary virus titers by ;103-fold (Fig. 4) is of interest in the
ontext of the phenomenon of heterosubtypic immunity
Het-I). Het-I is mediated by immune mechanisms that
ross-react with influenza type A viruses of different
ubtypes and has been shown to provide some degree
f protection against influenza type A viruses indepen-
ent of their subtype (Schulman and Kilbourne, 1965;
iang et al., 1994). In mice, Het-I is mediated, in part, by
ype A cross-reactive memory T cells, both CD81 and
D41, and, in party, by cross-reactive Ab (Liang et al.,
994; Gerhard et al., 1996). As M2-specific Ab is type A
ross-reactive (Zebedee and Lamb, 1988), it may ac-
ount, in part, for the humoral component of Het-I. The
iter of the active M2-specific Ab response in convales-
ent mice, which exhibit Het-I, is not known. Interestingly,
he M2-specific Ab response in convalescent humans
as been reported to be low and not consistently detect-
ble (Black et al., 1993). If so, enhancement of this re-
ponse may provide increased Het-I.
The finding that the NA-specific mAb was therapeuti-
ally less effective than the M2-specific mAb (Fig. 3),
espite having the same heavy chain isotype and exhib-
ting a higher avidity, is probably related to its shorter
alf-life, which was ;2 days compared to 7–8 days for
he anti-M2, the latter being typical for Abs of G2a isotype
Vieira and Rajewsky, 1988). Given that Ab half-life is
nfluenced by the Abs’ ability to interact with the (neona-
al) FcRn (Junghans and Anderson, 1996; Ghetie et al.,
996), it is conceivable that the NA-specific mAb ac-
uired a mutation that reduced not only its interaction
ith FcRn but also with other FcR’s, thus reducing its
fficacy to target and activate effector cells. It is note-
orthy also that the NA-specific mAb showed reduced
eaction with the G2a-specific Ab used here for heavy
hain isotyping (our unpublished observation). Various
ther explanations, however, are not excluded, such as a
ow density of NA expression by infected respiratory
pithelial cells or a suboptimal geometry of Ab binding to
arget cells (Kummer et al., 1990; Yousaf et al., 1993).
Although the CT activity mediated by the two mAbs
sed here was not effective enough to cure the infection,
e do not know for certain whether this is true for
ntibody-mediated CT activity, in general, in this infec-
ion. The active polyclonal response, in particular, could
e more effective than the passive mAb treatment used
ere because a concomitant CD41 T cell response may
ontribute synergistically acting activities, e.g., by secre-ion of cytokines that inhibit virus replication or recruit wnd activate FcR-expressing effector cells. However,
nalogous studies conducted with other viruses have
rovided similar findings, in that passive VN-negative
Abs decreased mortality or altered the course of the
isease when given to immunocompetent mice (Schmal-
ohn et al., 1982; Lefrancois, 1984; Boere et al., 1985;
tanley et al., 1986; Falgout et al., 1990; Tyler et al., 1993;
incus et al., 1995), but were usually incapable of curing
he infection when administered to immunodeficient
ice (Hunt et al., 1991; Schlesinger et al., 1993; Amor et
l., 1996; Griffin et al., 1997). A notable exception is the
eported ability of passive mAb of IgA isotype to clear a
ersistent intestinal rotavirus infection in SCID mice
Burns et al., 1996). However, the clearance mechanism
id not appear to involve typical Ab-mediated CT activity
s it was ineffective when mAb was administered to the
umenal side of the infected epithelium and apparently
equired transcytosis of these mAbs through intestinal
pithelial cells.
We have previously shown that a pulmonary influenza
irus infection in SCID mice can be readily cured by
reatment with HA-specific mAbs that exhibit both CT
nd VN activity. Given that CT activity can operate prior to
N activity in therapeutic applications of Abs, it is clear
rom this analysis that CT activity contributes to the
herapeutic efficacy of HA-specific Abs. Indeed, the syn-
rgism between CT and VN activity (Fig. 4) may underlie
he high therapeutic efficacy of HA-specific Abs in this
nfection.
MATERIALS AND METHODS
ice
C.B-17 mice, homozygous for the SCID mutation, and
ere referred to as SCID mice, were bred in the Animal
acility of The Wistar Institute. At 6 weeks of age, mice
ere tested for serum IgM concentration by ELISA. SCID
ice with serum IgM of ,0.2 mg/ml were used for these
xperiments, usually at the age of 8–12 weeks.
nfection, treatment, and analysis of mice
SCID mice, of either sex, were infected with 10–100
0% mouse infectious doses (MID50) of influenza virus
R8-Mt.S [A/PR/8/34 (H1N1) originally obtained from Mt.
inai Hospital, New York]. In initial experiments, infection
as induced by exposure of mice to a virus-containing
erosol in an airborne infection apparatus (TriR Instru-
ents) and in more recent experiments, by intranasal
i.n.) administration of ;30 ml of PR8 in phosphate-buff-
red saline (PBS) to mice anesthetized by ip injection of
.2 ml ketamine (10 mg/ml)/xylazine (2 mg/ml). Antibody
as always administered by ip injection (diluted in 0.2 ml
BS) either 1 day before or 6 to 24 h after infection. Six
r 14–16 days after infection, mice were anesthetized
ith ketamine/xylazine and exsanguinated by heart
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144 MOZDZANOWSKA ET AL.uncture; lung lobes were excised and immediately fro-
en by placing them into a tissue culture dish on dry ice.
or determination of virus titer, lungs were homogenized
nd debris-free supernatant was titrated into indicator
ultures of MDCK cells as described (Scherle et al.,
992). Lung extracts that scored negative in the MDCK
ssay (threshold of virus detection equals 102.1 50% tis-
ue culture infectious doses, TCID50) were tested by
noculation of undiluted extract into the allantoic cavity of
wo 10-day-old embryonated hen’s eggs (50 ml/egg, virus
etection threshold equals 101.3 egg infectious doses per
ung). Lung extracts that were negative in the latter test
ere considered to be free of infectious virus.
edia and solutions
ISC-CM consists of Iscove’s modified Dulbecco’s me-
ium (Gibco), supplemented with 0.05 mM 2-mercapto-
thanol, 0.005 mg/ml transferrin (Sigma), 2 mM glu-
amine (JRH Biosciences, Lenexa, KS), and 0.05 mg/ml
entamycin (Mediatech, Inc., Whittaker, MD). ISC-CM
as further supplemented, as indicated, with fetal calf
erum (FCS) or bovine serum albumin (BSA). PBSN is
BS containing 0.04% NaN3. PBSN was supplemented,
s indicated, with BSA.
irus
PR8 virus was grown in the allantoic cavity of 10-day-
ld embryonated hen’s eggs. Aliquots of allantoic fluid
ontaining infectious virus (108.8 TCID50 per milliliter)
ere stored frozen at 270°C and used as infectious
tock. Virus was purified from allantoic fluid and quanti-
iated by hemagglutination titration and protein assay
Bio-Rad, Hercules, CA). The virus dose is expressed in
emagglutinating units (1 HAU ;7 ng protein).
Abs
NA-112-S2.4 (NA-112) is specific for the viral NA and is
f k/IgG2a isotype. It is a switch variant selected from the
A-specific parental hybridoma NA-112 (IgG2b) that had
een generated by fusion of spleen cells from the sec-
ndary response of a PR8-immunized BALB/c mouse.
4C2-S1-4 is specific for the viral transmembrane protein
2 and is of k/IgG2a isotype. It is a switch variant
elected from the parental hybridoma 14C2 (k/IgG1) that
as originally obtained from Zebedee and Lamb (1988).
35-C12-6.2 (k/IgG2a) was generated from the primary
esponse of BALB/c mice 5 days after immunization with
R8 and is specific for the site Cb of HA (Kavaler et al.,
990). All mAbs were purified from tissue culture fluid or
rom ascites fluid of SCID mice by adsorption/elution
rom protein A columns. They were dialyzed against PBS
nd sterilized by filtration through a 0.45-mm filter mem-
rane (Millipore). Protein concentration was determined
y Bio-Rad protein assay using BSA as standard and by Cltraviolet light absorption, and the mean of both deter-
inations was used as concentration value.
ntibody assays
VN and HA inhibition assays were performed as de-
cribed (Mozdzanowska et al., 1997). Antibody activities
re expressed as the antibody concentration required for
ne unit of activity in the given assay. Thus, VN activity is
he antibody concentration at which 50% of MDCK cell
ultures are protected from infection by ;100 TCID50 of
R8. HA inhibition activity is the antibody concentration
equired for inhibiting three of four agglutinating doses of
R8 from agglutinating chicken Ec in a microassay. The
ield reduction assay was performed as follows: a sus-
ension of MDCK cells in ISC-CM was incubated for 1 h
t 37°C with 103 TCID50 of PR8/10
6 cells. The cells were
hen pelleted, resuspended at 4 3 105 cells/ml in ISC-
M-0.2% BSA, and dispensed (100 ml/well) into flat-bot-
om 96-well plates that contained antibody at various
oncentration (50 ml/well). Plates were incubated for ;14
at 37°C to permit full adherence of MDCK cells. Trypsin
2.5%, Whittaker, Walkersville, MD, diluted 1/750 in ISC-
M-0.2% BSA) was then added at 50 ml/well (to mediate
roteolytic activation of viral infectivity for multicycle rep-
ication) and the incubation continued. Supernatants
ere harvested at various time points and virus yield
as measured by HA titration.
LISA
The assay was performed as described (Kavaler et al.,
990) using as solid phase immunoadsorbent purified
R8 (25 HAU/well) or PR8-infected MDCK cell monolay-
rs that had been fixed by treatment for 5 min with 5%
uffered formalin (Fisher, Fair Lawn, NJ).
low cytometry
FCM was performed as described (Mozdzanowska et
l., 1997) using PR8-infected EL4 cells (murine lym-
homa) and P1.HTR cells [a derivative of the P815 mas-
ocytoma line (Woefel et al., 1987)] as targets.
ffinity measurement
Purified antibodies were iodinated by the chloramine T
ethod and were subsequently quantitated by ELISA.
he assay was set up in duplicate in round-bottom 96-
ell plates. Reactions consisted of 100 ml cold PBS–0.5%
SA containing unlabeled mAb at concentrations rang-
ng from ;4000 to 0 nM, iodinated mAb at ;0.5 nM, and
R8-infected EL4 cells at 5 3 104, 2 3 105, and 5 3 105
ells for analysis of the HA-, M2-, and NA-specific mAb
eactions, respectively. Infected EL4 cells were prepared
y infection (1 h at 37°C, ;2 3 106 TCID50/10
6 EL4 in
SC-CM) and incubation for 14–16 h at 32°C in ISC–
M–5% FCS. Dead cells were removed by centrifugation
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145THERAPEUTIC ACTIVITY OF ANTIBODY IN INFLUENZA INFECTIONn a 30%/70% Percoll gradient. Additional wells contained
ninfected cells to estimate the assay background. The
lates were incubated for 150 min on ice, with constant
ocking. At the end of the incubation period, the samples
ere layered on top of 200 ml of ice-cold separation oil in
.4-ml Eppendorf tubes and cells (with bound mAb) sep-
rated from free mAb by centrifugation for 3 min at 10,000
. The separation oil consisted of 82 vol of silicone oil (d
.050, Aldrich, Milwaukee, WI) mixed with 18 vol of light
araffin oil (Fisher). The tubes were snap-frozen in eth-
nol–CO2, the cell pellet was clipped off with an Eppen-
orf tube clipper, and the cell-associated radioactivity
as measured in a gamma counter. Concentrations of
ound and free mAb at each point of the dilution series
ere calculated and the data were analyzed with the
IGAND program for Macintosh (Biosoft, Cambridge, UK)
ccording to the Scatchard equation.
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